1.
Rustighi I, Campa C, Rossi M, Semeraro S, Vetere A, Gamini A. Analysis of N-acetylaminosugars by CE: a comparative derivatization study. Electrophoresis. 2009;30(15):2632-9. doi:10.1002/elps.200800791.
1.
Wang H, Nicolay BN, Chick JM, et al. The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival. Nature. 2017;546(7658):426-430. doi:10.1038/nature22797.
1.
Stolte B, Iniguez AB, Dharia NV, et al. Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in wild-type Ewing sarcoma. J Exp Med. 2018;215(8):2137-2155. doi:10.1084/jem.20171066.
1.
Tripathy D, Bardia A, Sellers WR. Mechanism of Action and Clinical Impact of Ribociclib-Response. Clin Cancer Res. 2017;23(18):5658. doi:10.1158/1078-0432.CCR-17-1819.
1.
Eismann J, Heng YJ, Waldschmidt JM, et al. Transcriptome analysis reveals overlap in fusion genes in a phase I clinical cohort of TNBC and HGSOC patients treated with buparlisib and olaparib. J Cancer Res Clin Oncol. 2020;146(2):503-514. doi:10.1007/s00432-019-03078-9.
1.
Udeshi ND, Mani DR, Eisenhaure T, et al. Methods for quantification of in vivo changes in protein ubiquitination following proteasome and deubiquitinase inhibition. Mol Cell Proteomics. 2012;11(5):148-59. doi:10.1074/mcp.M111.016857.
1.
Serra V, Eichhorn PJA, García-García C, et al. RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J Clin Invest. 2013;123(6):2551-63. doi:10.1172/JCI66343.
1.
Wu S-C, Li LS, Kopp N, et al. Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Cancer Cell. 2015;28(1):29-41. doi:10.1016/j.ccell.2015.06.005.